Endothelin-1: A new target of therapeutic intervention for the treatment of heart failure

Current Opinion in Cardiology

Volumn 15, Issue 3, 2000, Pages 136-140

  Duchman, Stanley M ^a,b   Thohan, Vinay ^a   Kalra, Dinesh ^a   Torre Amione, Guillermo ^a  

^a Winters Ctr for Heart Failure Res   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; TEZOSENTAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD LEVEL; CIRCULATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROGNOSIS; RABBIT; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOGS; DRUG EVALUATION, PRECLINICAL; ENDOTHELIN-1; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; OXYGEN CONSUMPTION; PROGNOSIS; PYRIDINES; RABBITS; RATS; SURVIVAL ANALYSIS; TETRAZOLES;

EID: 0034031636     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200005000-00003     Document Type: Review

References (43)

1. 1 Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells [see comments]. Nature 1988, 332:411-415.
2. 2 Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T: The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989, 86:2863-2867.
3. 3 Sakurai T, Yanagisawa M, Masaki T: Molecular characterization of endothelin receptors. Trends Pharmacol Sci 1992, 13:103-108.
4. 4 McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ: Plasma endothelin in chronic heart failure. Circulation 1992, 85:1374-1379.
5. 5 Krum H, Goldsmith R, Wilshire-Clement M, Miller M, Packer M: Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 1995, 75:1282-1283.
6. 6 Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y: Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996, 384:353-355.
7. 7 Inoue A, Yanagisawa M, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T: The human preproendothelin-1 gene: complete nucleotide sequence and regulation of expression. J Biol Chem 1989, 264:14954-14959.
8. 8 Hiroe M, Hirata Y, Fujita N, Umezawa S, Ito H, Tsujino M, et al.: Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. Am J Cardiol 1991, 68:1114-1115.
9. 9 Pacher R, Stanek B, Hulsmann M, Koller-Strametz J, Berger R, Schuller M, et al.: Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996, 27:633-641.
10. 10 Miyauchi T, Yanagisawa M, Tomizawa T, Sugishita Y, Suzuki N, Fujino M, et al.: Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction [letter]. Lancet 1989, 2:53-54.
11. 11 Benigni A, Remuzzi G: Endothelin antagonists. Lancet 1999, 353:133-138
12. 12 Iwasaki S, Homma T, Matsuda Y, Kon V: Endothelin receptor subtype B mediates autoinduction of endothelin-1 in rat mesangial cells. J Biol Chem 1995, 270:6997-7003.
13. 13 Hosoda K, Nakao K, Tamura N, Arai H, Ogawa Y, Suga S, et al.: Organization, structure, chromosomal assignment, and expression of the gene encoding the human endothelin-A receptor. J Biol Chem 1992, 267:18797-18804.
14. 14 Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, et al.: Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997, 96:1976-1982.
15. 15 Maemura K, Kurihara H, Morita T, Oh-hashi Y, Yazaki Y: Production of endothelin-1 in vascular endothelial cells is regulated by factors associated with vascular injury. Gerontology 1992, 38(suppl)1:29-35.
16. 16 Haynes WG, Webb DJ: Contribution of endogenous generation of endothelin1 to basal vascular tone [see comments]. Lancet 1994, 344:852-854.
17. 17 Haynes WG, Webb DJ: Endothelium-dependent modulation of responses to endothelin-I in human veins. Clin Sci (Colch) 1993, 84:427-433.
18. 18 Sakai S, Miyauchi T, Sakurai T, Yamaguchi I, Kobayashi M, Goto K, Sugishita Y: Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist: increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. J Am Coll Cardiol 1996, 28:1580-1588.
19. 19 Resink TJ, Scott-Burden T, Buhler FR: Activation of multiple signal transduction pathways by endothelin in cultured human vascular smooth muscle cells. Eur J Biochem 1990, 189:415-421.
20. 20 Kramer BK, Smith TW, Kelly RA: Endothelin and increased contractility in adult rat ventricular myocytes. Role of intracellular alkalosis induced by activation of the protein kinase C-dependent Na(+)-H+ exchanger. Circ Res 1991, 68:269-279.
21. 21 Bogoyevitch MA, Sugden PH: The role of protein kinases in adaptational growth of the heart. Int J Biochem Cell Biol 1996, 28:1-12.
22. 22 Seo B, Oemar BS, Siebenmann R, von Segesser L, Luscher TF: Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels [see comments]. Circulation 1994, 89:1203-1208.
23. 23 Shubeita HE, McDonough PM, Harris AN, Knowlton KU, Glembotski CC, Brown JH, Chien KR: Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes: a paracrine mechanism for myocardial cell hypertrophy. J Biol Chem 1990, 265:20555-20562.
24. 24 Dupuis J, Goresky CA, Stewart DJ: Pulmonary removal and production of endothelin in the anesthetized dog. J Appl Physiol 1994, 76:694-700.
25. 25 Dupuis J, Stewart DJ, Cernacek P, Gosselin G: Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996, 94:1578-1584.
26. 26 Dupuis J, Goresky CA, Fournier A: Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 1996, 81:1510-1515.
27. 27 Shichiri M, Marumo F, Hirata Y: Endothelin-B receptor-mediated suppression of endothelial apoptosis. J Cardiovasc Pharmacol 1998, 31(suppl 1):S138-S141. Excellent study further defining the physiologic effects of ET-B receptor blockade and effects on apoptosis.
28. 28 Kobayashi T, Miyauchi T, Sakai S, Yamaguchi I, Goto K, Sugishita Y: Endothelin-converting enzyme and angiotensin-converting enzyme in failing hearts of rats with myocardial infarction. J Cardiovasc Pharmacol 1998, 31(suppl 1):S417-S420. Nice description of the effects of ECE-I alone and with ACE in failing rat myocardium.
29. 29 Borgeson DD, Grantham JA, Williamson EE, Luchner A, Redfield MM, Opgenorth TJ, Burnett JC Jr: Chronic oral endothelin type A receptor antagonism in experimental heart failure. Hypertension 1998, 31:766-770. Nice study demonstrating effects of ET-A inhibition chronically heart failure.
30. 30 Spinale FG, Walker JD, Mukherjee R, Iannini JP, Keever AT, Gallagher KP: Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function [see comments]. Circulation 1997, 95:1918-1929.
31. 31 Ito H, Hiroe M, Hirata Y, Fujisaki H, Adachi S, Akimoto H, et al.: Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 1994, 89:2198-2203.
32. 32 Yamauchi-Kohno R, Miyauchi T, Hoshino T, Kobayashi T, Aihara H, Sakai S, et al.: Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function. Circulation 1999, 99:2171-2176. Excellent study demonstrating increased survival in hamsters with cardiomyopathy after ET-A receptor blackade.
33. 33 Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y: Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996, 384:353-355.
34. 34 Sakai S, Miyauchi T, Sakurai T, Yamaguchi I, Kobayashi M, Goto K, Sugishita Y: Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist: increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. J Am Coll Cardiol 1996, 28:1580-1588.
35. 35 Ohnishi M, Wada A, Tsutamoto T, Fukai D, Sawaki M, Maeda Y, Kinoshita M: Chronic effects of a novel, orally active endothelin receptor antagonist, T-0201, in dogs with congestive heart failure. J Cardiovasc Pharmacol 1998, 31(suppl 1):S236-S238. Another study demonstrating the benefit of chronic endothelin receptor inhibition in dogs with heart failure.
36. 36 Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, et al.: Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995, 346:732-736.
37. 37 Stawski G, Olsen UB, Grande P: Cytotoxic effect of endothelin-1 during "stimulated" ischaemia in cultured myocytes. Eur J Pharmacol 1991, 201:123-124.
38. 38 Onishi K, Ohno M, Little WC, Cheng CP: Endogenous endothelin-1 depresses left ventricular systolic and diastolic performance in congestive heart failure. J Pharmacol Exp Ther 1999, 288:1214-1222. Nicely describes worsening ventricular function in presence of increased endothelin-1 levels.
39. 39 Sutsch G, Bertel O, Kiowski W: Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist Bosentan in humans. Cardiovasc Drugs Ther 1997, 10:717-725.
40. 40 Sutsch G, Kiowski W, Yan XW, Hunziker P, Christen S, Strobel W, et al.: Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998, 98:2262-2268. Human study suggests hemodynamic benefit of short-term mal endothelin antagonism in humans with decompensated CHF.
41. 41 Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V: The effect of an endothelin-receptor antagonist, Bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators [see comments]. N Engl J Med 1998, 338:784-790. Demonstrates endothelin antagonism hemodynamic effects in humans with HTN without compensatory tachycardia.
42. 42 Torre-Amione G, Durand J-B, Bozkurt B, Vooletich MT, Young JB, Pratt CM, Charlon V, Widman T: Results of a randomized placebo-controlled hemodynamic trial with an intravenous endothelin-1 receptor antagonist in patients with CHF. Circulation 1999, 100(suppl 1). Demonstrates hemodynamic effects of intravenous endothelin receptor blockade in humans with acutely decompensated CHF.
43. 43 Kinder C, Chamberlin J, Kall J, Kopp D, Johnson M, Costanzo MR, Wilber D: Prognostic significance of sustained ventricular tachyarrhythmia occurring during dobutamine infusion. J Heart Lung Transplant 1994, 13:1045-1050.